You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

~ Buy the INLYTA (axitinib) Drug Profile, 2024 PDF Report in the Report Store ~

INLYTA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Inlyta patents expire, and when can generic versions of Inlyta launch?

Inlyta is a drug marketed by Pf Prism Cv and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-two patent family members in fifty-seven countries.

The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the axitinib profile page.

DrugPatentWatch® Generic Entry Outlook for Inlyta

Inlyta was eligible for patent challenges on January 27, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 14, 2030. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (axitinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for INLYTA
Drug Prices for INLYTA

See drug prices for INLYTA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for INLYTA
Generic Entry Date for INLYTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for INLYTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lynkcell EuropePhase 1
Consorzio OncotechPhase 2
Hoffmann-La RochePhase 2

See all INLYTA clinical trials

Pharmacology for INLYTA
Paragraph IV (Patent) Challenges for INLYTA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
INLYTA Tablets axitinib 1 mg and 5 mg 202324 1 2018-02-23

US Patents and Regulatory Information for INLYTA

INLYTA is protected by four US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of INLYTA is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting INLYTA

Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

PD-L1 antagonist combination treatments
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for INLYTA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pfizer Europe MA EEIG  Inlyta axitinib EMEA/H/C/002406
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Authorised no no no 2012-09-03
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for INLYTA

When does loss-of-exclusivity occur for INLYTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 5931
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 08236444
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0809471
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 82859
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1679356
Estimated Expiration: ⤷  Try a Trial

Patent: 3626739
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 19119
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 34702
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 34702
Estimated Expiration: ⤷  Try a Trial

Patent: 52047
Estimated Expiration: ⤷  Try a Trial

Patent: 74702
Estimated Expiration: ⤷  Try a Trial

Patent: 49063
Estimated Expiration: ⤷  Try a Trial

Finland

Patent: 34702
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 93405
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 1320
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 69197
Estimated Expiration: ⤷  Try a Trial

Patent: 09019030
Estimated Expiration: ⤷  Try a Trial

Patent: 14193900
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 09010761
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 0126
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 34702
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 34702
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 18898
Estimated Expiration: ⤷  Try a Trial

Patent: 09136593
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 34702
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0906990
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1237588
Estimated Expiration: ⤷  Try a Trial

Patent: 090127949
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 34866
Estimated Expiration: ⤷  Try a Trial

Patent: 19351
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 81602
Estimated Expiration: ⤷  Try a Trial

Patent: 0911781
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INLYTA around the world.

Country Patent Number Title Estimated Expiration
Taiwan 201709933 PD-L1 antagonist combination treatments ⤷  Try a Trial
Algeria 3191 Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci. ⤷  Try a Trial
Hungary 228502 INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE ⤷  Try a Trial
Estonia 200100717 ⤷  Try a Trial
Denmark 2134702 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for INLYTA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1218348 CR 2013 00010 Denmark ⤷  Try a Trial PRODUCT NAME: AXITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/12/777/001-006 20120903
1218348 C01218348/01 Switzerland ⤷  Try a Trial FORMER OWNER: AGOURON PHARMACEUTICALS, INC., US
1218348 PA2013003,C1218348 Lithuania ⤷  Try a Trial PRODUCT NAME: AXITINIBUM; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903
1218348 438 Finland ⤷  Try a Trial
1218348 PA2013003 Lithuania ⤷  Try a Trial PRODUCT NAME: AXITINIBUM; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.